Clinical and economic benefits of advanced microplegia delivery system in cardiac surgery: evidence from 250 hospitals. (23rd April 2018)

• Record Type: Journal Article
• Authors: Gerdisch, Marc W; Robinson, Scott; David, Guy; Makepeace, Stephanie; Ryan, Michael P; Gunnarsson, Candace
• Is Part Of: Journal of comparative effectiveness research. Volume 7:Number 7(2018)
• Page Start: 673
• Page End: 683
• Publication Date: 2018-04-23
• Subjects: aortic valve replacement -- coronary artery bypass graft -- difference-in-differences -- hospital perspective -- length of stay -- microplegia delivery -- mitral valve replacement -- total visit cost -- traditional cardioplegia; Medical care -- Research -- Periodicals; Medical care -- Research -- Evaluation -- Periodicals; Medical care -- Decision making -- Periodicals; Evidence-based medicine -- Periodicals; Medicine, Comparative -- Periodicals; 362.1072
• DOI: 10.2217/cer-2018-0011
• Languages: English
• ISSNs: 2042-6305

Abstract

Aim: Determine the impact of a second generation microplegia delivery system (MPS2) compared with traditional cardioplegia.Materials & methods: Multivariable difference-in-differences analysis using fixed effects was performed for each outcome: adverse event (AE) composite, total visit cost, medication cost, length of stay (LOS) and intensive care unit (ICU) days.Results: A 2.25% absolute risk reduction in AE composite was found with MPS2 compared with traditional cardioplegia, which equates to relative risk reduction of 5.25%. Significant reductions in LOS and ICU days (0.1 α level). Per case reduction of US$1231 total visit and US$192 medication costs were found in MPS2 hospitals.Conclusion: For hospitals with MPS2, significant reductions were seen in AEs, LOS and ICU days, which lead to reductions in total visit and medication costs.